Prescribing information



Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate.

Individual patient dosing may vary – please consult the Prescribing Information for full details.

Graphic outlining the benefits of the UnoReady® pen including one monthy maintenance injection, overall 100% of patients found the UnoReady® 300mg pen easy to use, less than 1% site reactions at one year, latex-free device.


Striving to improve convenience for your patients1,5

Table showing the number of injections required for users of the Cosentyx 300mg and 150mg pens. Text: 50% fewer injections.

Graphic showing the features of the 300mg pen.


Explore the differences between the UnoReady® 300 mg pen and the SensoReady® 150 mg pen1,5,6

Image showing the features and requirements of the UnoReady® 300mg pen.
 Image showing the features and requirements of the 150mg pen.

The UnoReady® 300 mg pen is available via the homecare channels and your pharmacy.
If you would like to order a demo kit or for further information on the UnoReady® 300 mg pen, please contact us here.


View the Cosentyx UnoReady® efficacy data, the Cosentyx safety profile and how the You First programme can benefit your patients

*Compared to 2 x 150 mg PFS.
N=37, moderate-to-severe plaque psoriasis patients at Week 28.2
Individual patient dosing may vary – please consult the Prescribing Information for full details.
§In a clinical study, adverse events with the preferred term injection-site bruising or injection-site pain due to administration of Cosentyx using the UnoReady® pen over 52 weeks. In a randomised double blind phase 3 clinical trial, 122 subjects were randomized to secukinumab 300 mg 2 mL AI (N=41), secukinumab 300 mg 2 × 1 mL PFS (N=41), or placebo (N=40)
You First is for NHS patients who are receiving Cosentyx or for whom the prescribing decision has been made. A service level agreement is required for each NHS organisation participating. You First is a patient support programme developed and funded by Novartis Pharmaceuticals UK Limited.

AI, autoinjector; AS, ankylosing spondylitis; DLQI, Dermatology Life Quality Index; IGA, Investigator’s Global Assessment; IGA mod 2011, IGA 2011 modified version; ISR, injection site reaction; NHS, National Health Service; PASI, Psoriasis Area and Severity Index; PFS, pre-filled syringe; PK, pharmacokinetic; PsA, psoriatic arthritis; PsO, moderate-to-severe plaque psoriasis; SIAQ, Self-Injection Assessment Questionnaire.  


  1. Cosentyx® Summary of Product Characteristics.
  2. Novartis DOF. CAIN457A2325 Data Analysis Report. Satisfaction with self-injection. December 2020.
  3. Sigurgeirsson B et al. Dermatol Ther 2021;e15285. doi: 10.1111/dth.15285.
  4. Novartis data on file. CAIN457A2325 Data Analysis Report. Injection site reaction rate. December 2020.
  5. Cosentyx 300 mg UnoReady pen Patient Information Leaflet.
  6. Cosentyx 150 mg SensoReady pen Patient Information Leaflet.
  7. UK_DOF_Sec004.
  8. Bissonnette R et al. J Eur Acad Dermatol Venereol 2018;32(9):1507–1514.
  9. Mease P et al. ACR Open Rheum 2020;2(1):18–25.
  10. Baraliakos X et al. RMD Open 2019;5(2):e001005.
  11. Sticherling M et al. EADV 2021. Poster 1420.
  12. Langley RG et al. N Engl J Med 2014;371(4):326–338.
  13. McInnes IB et al. Rheumatology 2017;56:1993–2003.
  14. Baeten D et al. N Engl J Med 2015;373(26):2534–2548.
  15. Deodhar A et al. Arthritis Res Ther 2019;21:111.
Rate this content: 
No votes yet
UK | May 2022 | 209966

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]